688197 首药控股
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-21.154-23.163-16.662-28.777-195.939
总资产报酬率 ROA (%)-18.381-20.836-15.391-25.610-123.473
投入资产回报率 ROIC (%)-21.000-23.029-16.570-28.483-191.191

边际利润分析
销售毛利率 (%)100.00098.95697.87199.37199.932
营业利润率 (%)-7,757.898-5,376.314-3,548.333-9,518.597-1,116.806
息税前利润/营业总收入 (%)-7,763.149-5,511.391-3,911.122-10,613.206-1,122.645
净利润/营业总收入 (%)-7,738.356-5,376.400-3,548.792-9,512.739-1,111.996

收益指标分析
经营活动净收益/利润总额(%)108.645106.795107.506114.578112.123
价值变动净收益/利润总额(%)-8.273-8.186-3.827-0.6550.000
营业外收支净额/利润总额(%)-0.2530.0020.013-0.062-0.433

偿债能力分析
流动比率 (X)6.4567.05410.89813.4950.687
速动比率 (X)6.4257.02410.89513.4690.659
资产负债率 (%)14.11512.2768.1977.13797.419
带息债务/全部投入资本 (%)0.4360.5730.2210.485-3.823
股东权益/带息债务 (%)22,807.32617,304.74145,149.97320,485.261-803.100
股东权益/负债合计 (%)608.468714.5811,119.9701,301.0842.650
利息保障倍数 (X)313.11740.82810.7949.644105.421

营运能力分析
应收账款周转天数 (天)12.3018.3210.000374.34352.484
存货周转天数 (天)--16,031.7384,113.77458,806.56685,920.599